INTRODUCTION
============

Cancer of the penis is a rare neoplasm with a high incidence in developing countries. This fact clearly indicates the disease\'s association with local economic conditions ([@B1]). Penile cancer has a low overall incidence, representing approximately 0.4% of malignancies in the Unites States. In Brazil, despite the high incidence in some regions, this disease accounts for about 2.1% of malignancies ([@B2], [@B3]). A recent Brazilian epidemiologic study on penile carcinoma revealed the profile of these patients ([@B4]).

The etiology of penile cancer has not been fully elucidated. However, its incidence varies according to the practice of circumcision, personal hygiene, presence of phimosis, human papillomavirus (HPV) infection, and tobacco use ([@B5]--[@B9]). The mechanism of tumor induction and promotion related to HPV infection is not completely understood. It is believed that the incorporation of viral DNA to the human genome leads to hyper-expression of viral genes E6 and E7 and inactivates the host cell\'s tumor suppressor gene products p53 and pRb ([@B10]).

The presence and extent of inguinal metastases are the most important prognostic factor related to the survival of patients with penile carcinoma. At the time of its initial presentation, 50% of patients with SCCP have inguinal lymphadenopathy; however, only half of these actually show metastatic lymph node involvement. Furthermore, 20% of patients with clinically negative inguinal lymph nodes have micro-metastases that will only be diagnosed by histopathologic examination of surgical specimens obtained from lymphadenectomy, a procedure associated with a significant morbidity ([@B1], [@B4]). Therefore, SCCP remains a challenge for the urologist, because there is no consensus for an appropriate therapy for all forms of disease presentation. The possibility of using reliable biomarkers to predict disease prognosis and to establish procedures less aggressive for patients at low risk for metastasis becomes necessary. In this sense, the development of more accurate molecular diagnostic methods and prognostic value tumor markers is essential.

Proteomics is the large-scale identification of proteins. Proteomics technologies are currently under development and several methodological approaches can be applied depending on the objectives. The great advantage of proteomics over genomics or transcriptomics studies is that the real functional molecules of the cell are being studied. Therefore, in this study, the aim was to identify possible protein biomarkers and/ or candidates for therapeutic targets in tissues of patients with SCCP, infected by HPV, applying one dimensional electrophoresis (1DE), followed by direct mass spectrometry (MS) analysis.

MATERIALS AND METHODS
=====================

Patients and controls
---------------------

Between January 2009 and December 2011, 20 patients treated at three health institutions in the state of Rio de Janeiro were recruited and divided into two groups for prospective tissue proteomic analysis. Group 1 was composed of 10 patients with positive HPV malignant SCCP treated at the Brazilian National Cancer Institute (INCA) and Mario Kröeff Hospital. Group 2 (control group) was composed of 10 patients with HPV negative non-tumorous penile foreskins collected at Santa Veronica Hospital after circumcision procedures. HPV typing was performed as previously published ([@B11], [@B12]) and reported ([@B13]).

Pathological material was reviewed in both groups and all tumors were histologically classified based on Broders' system. Only two pathologists were responsible for reviewing the specimens. The clinical and pathological staging for Group 1 was done according to the 2002 TNM classification system. Patients' treatment varied according to primary tumor presentation. The distribution of T and N categories is shown in [Table-1](#t1){ref-type="table"}. The criterion for performing a radical inguinal lymphadenectomy (RIL) in all cases was the stage, grade and/or presence of lymphovascular invasion. Two patients with stage T1 underwent lymphadenectomy. The first presented unilateral inguinal lymphadenopathy and the second presented grade 2 tumor. In our services, we only do not perform RIL in patients with stage T1N0M0 grade 1 tumor without lymphovascular invasion ages ranged from 38 to 90 years (mean, 63.56) for Group 1 and 23 to 83 years (mean, 60) for Group 2. The pathological variables studied were histological type, grade of tumor differentiation, corpus spongiosum and/or infiltration of the corpora cavernosa, urethral in-filtration, and inguinal lymph nodes involvement. Patient recruitment did not take into account any criteria of poor prognosis, and the tissue specimens were randomly selected respecting the number of pre-established patients for the study. All patients involved in the current study gave their informed consent. This study was approved by the Brazilian National Cancer Institute Ethical Board (registrations \# 38/05 and 67/07). Because this was a pilot study and unprecedented in literature the number of patients was pre-established in both groups in the design of work, aiming preliminary results for further investigation. The only exclusion criterion was positivity for HPV in the control group. Our study aimed qualitative detection of proteins in the 2 groups not being our objective to quantify the identified proteins. All tests in tumor samples from patients revealed the presence of HPV. Because of the rarity of HPV-negative patients, a second study with HPV-negative patients will be necessary.

###### Histopathologic findings, pathologic staging and treatment option for patients from group 1.

  Pts   Histology                 Grade   Stage TNM   HPV type      Surgery
  ----- ------------------------- ------- ----------- ------------- ------------------------------------
  1     Squamous cell carcinoma   G2      T4N2Mx      MY-/16+       Total Amputation + Bilateral RIL
  2     Squamous cell carcinoma   G1      T2N3Mx      MY-/18+       Partial Amputation + Bilateral RIL
  3     Squamous cell carcinoma   G2      T2N0Mx      16+;45+       Partial Amputation + Bilateral RIL
  4     Squamous cell carcinoma   G2      T2N0Mx      MY-/18+       Partial Amputation + Bilateral RIL
  5     Squamous cell carcinoma   G1      T1N1Mx      MY-/45+       Partial Amputation + Bilateral RIL
  6     Squamous cell carcinoma   G2      T1N0Mx      45+           Partial Amputation + Bilateral RIL
  7     Squamous cell carcinoma   G1      T2N0Mx      MY-/16+ 45+   Partial Amputation + Bilateral RIL
  8     Squamous cell carcinoma   G2      T2N1Mx      MY+/45+       Partial Amputation + Bilateral RIL
  9     Squamous cell carcinoma   G2      T2N1Mx      MY+/16+       Partial Amputation + Bilateral RIL
  10    Squamous cell carcinoma   G2      T2N0Mx      MY-/45+       Partial Amputation + Bilateral RIL

RIL = Radical Inguinal Lymphadenectomy; MY-MY09/11 Consensus Primers

Tissue protein extraction and quantification
--------------------------------------------

Tissues were macerated in 200μL of lysis buffer (7 M urea, 2 M Thiourea, 4% CHAPS and 1% DTT) with the addition of 0.2-mM PMSF. This mixture was stirred for 1 hour at room temperature and then centrifuged at 14.000g for 15 minutes. The supernatant was collected and stored at −80°C ([@B14]) until experimentation.

The protein extracts were quantified by 2D Quant Kit (GE Healthcare, Cat \#. 80-6483-56), according to the manufacturer\'s instructions. Measurement was performed at 650 nm in Elisa Spectra Max 190 device from Molecular Devices. The analysis of quantification was performed by the program SOFT® Pro 4.3 max, Life Sciences Edition.

Gel 1D
------

After quantification, two protein pools were formed with 10 SCCP tissues and with 10 control tissues, separately. Each pool contained 3.3μg of proteins from each sample, a total of 33μg. The SCCP and control pools were applied on a 12% SDS-PAGE gel. Proteins were separated in Tris-Glycine buffer (25-mM Tris and 250-mM Glycine pH 8,3) and 0.1% SDS at 80 V and 50 mA ([@B15]). The proteins were visualized with Coomassie blue G-250. The gels were scanned on Image ScannerTM (GE Healthcare) using the program Labscan™ (GE Healthcare) for protein lanes reading.

Mass spectrometry analysis
--------------------------

The lanes were fractioned in approximately 2-5 mm slices. The bands in the slices were destained in a solution of 25-mM ammonium bicarbonate (NH~4~HCO~3~) pH 8.8/50% and acetonitrile (ACN) overnight on a shaker, at room temperature. To reduce proteins, the gel was incubated with 10mM DTT in 25-mM NH~4~HCO~3~ at 56°C for 1 hour. The supernatant was discarded and the gel was washed in a solution of 25-mM NH~4~HCO~3~ twice. After protein disulfide bonds were reduced, cysteines were alkylated with iodoacetamide 55 mM for 45 minutes at room temperature in the dark. The supernatant was discarded and the gel was washed with 25-mM NH~4~HCO~3~ solution in 50% ACN. The supernatant was removed again and gel slices were dehydrated with 100% ACN for 5 minutes and posteriorly in a vacuum centrifuge. Proteins were digested with trypsin (Promega) 10ng/μL dilution, overnight, at 37°C. After digestion with trypsin, peptides were extracted from gels by adding a solution containing 0.1% formic acid/50% ACN for 30 minutes. This solution was transferred to another tube and the procedure was repeated twice. The samples were completely dried in a vacuum centrifuge. The pellets were resuspended in water and purified through Ziptip Perfect Pure C18 (Eppendorf, cat \# 0030.008.405) and then dried in a vacuum centrifuge.

For mass spectrometry analysis, the peptides were resuspended in 20μL of acetonitrile 3% and acid formic 0.1% solution. The peptides were analyzed by mass spectrometer ESI-Q/TOF Micro (Waters) linked to a nanoACQUITYUPLC® (Waters). The peptides was loaded on symmetric C18 trap column (Waters) followed by fraction in a nanoEase BEH 130 C18 100 mm × 100μm column (Waters) at a flow rate of 0.5μL/min and eluted with a linear acetonitrile gradient (from 10 to 50%) of 0.1% formic acid. Spectrometer analysis was performed on positive mode. Acquisition parameters on mass spectrometer was: cone voltage 30 V, capillary voltage 3500 V, source temperature 80°C, scanning a mass-to-charge ratio (m/z) MS mode 400-2000 and MS/MS mode 50-2000. The three ions with more intensity with charge states of +2, +3, or +4 were selected for MS/MS fragmentation. The reference ion used was the monocharged ion m/z 588.8692 of phosphoric acid. The data acquisition was performed by MassLynx 4.0 software (Micromass/Waters) and the process data by proteinLynx Global Service (PLGS 2.4, Waters).

Proteins were identified by correlation of tandem mass spectra to the NCBInr proteins database, using Mascot online (Matrix Science, London, UK - http://www.matrixscience.com/cgi/se-arch_form.pl?FORMVER=2&SEARCH=MIS) with restricted taxonomy Homo sapiens. The NCBI (National Center for Biotechnology Information) protein database is an on line collection of sequences from several sources, including translations from annotated coding regions in GenBanK, RefSeq and TPA, as well as records from Swiss-Prot, PIR, PRF, and PDB; "nr" refers to non-redundant protein sequences. The NCBI is a division of the National Library of Medicine (NLM) at the National Institutes of Health (NIH), USA. The parameters were as follows: MS and MS/MS tolerance of 0.1 Da, tryptic specificity allowing for one missed cleavage, fixed modification of carbamidomethylation of cysteine residues, and variable modification of oxidation of methionine, phosphorylation of tyrosine, serine and threonine residues and propionamide. Positive protein identification was accepted with at least two peptides with a Mascot peptide score ≥35.

RESULTS
=======

The pathological features of the primary tumor and inguinal lymph nodes, the type of treatment instituted, and the HPV type ([@B13]) for each patient from Group 1 are described in [Table-1](#t1){ref-type="table"}.

The protein extracts obtained from Groups 1 and 2 were separated by electrophoresis in a 12% SDS-PAGE gel. The protein bands of each group were identified and compared for differences. Twenty-six protein spots from Group 1 and 21 from Group 2 were identified, sliced out from the gel and analyzed through mass spectrometry ([Figure-1](#f1){ref-type="fig"}). Sixty-three different proteins were identified in Group 1 and 50 in Group 2. After a comparative analysis of both groups, it was possible to recognize 28 proteins exclusively detected in Group 1 and 21 proteins presented only in Group 2 ([Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}).

![1DE analysis of tissue samples from SCCP HPV patients and control group. Each pool contained 3.3µg of proteins from each sample, a total of 33µg. The SCCP and control pools were applied on a 12% SDS-PAGE gel. The gel was stained with Coomassie blue G. The markers and numbers in gel represent the sections that were excised for mass spectrometry analysis.](1677-5538-ibju-41-4-0642-gf01){#f1}

###### Proteins identified in pool of patients with SCCP (Group 1)

  Gel Slice   NCBI ID        Proteins                                                                                                   Score   Representative Peptides                                                                                                                                                                               KEGG        Function                                                             Cell Compartment
  ----------- -------------- ---------------------------------------------------------------------------------------------------------- ------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------- -------------------------------------------------------------------- -----------------------------------------
  T1          gi\|179212     Na+ K+ ATPase alpha subunit                                                                                41      R.SPDFTNENPLETR.N                                                                                                                                                                                     hsa:476     ATP biosynthesis                                                     Cell membrane
  T2;3        gi\|189036     Nonmuscle myosin heavy chain (Myosin 9)                                                                    78      K.ALELDSNLYR.I K.HSQAVEELAEQLEQTKR.V                                                                                                                                                                  hsa:4627    Cell communication                                                   Cytosol
  T2          gi\|1296662    Plectin                                                                                                    74      R.SQVEEELFSVR.V K.VLALPEPSPAAPTLR.S                                                                                                                                                                   hsa:5339    Apoptosis                                                            Cytosol, cytoskeletal
  T2          gi\|93141049   Collagen alpha-1 (XII) chain short isoform precursor                                                       60      K.ALALGALQNIR.Y R.WYSPVDGTRPSESIVVPGNTR.M                                                                                                                                                             hsa:1303    Cell adhesion                                                        Extracellular matrix
  T5          gi\|4507677    Endoplasmin                                                                                                44      K.SILFVPTSAPR.G                                                                                                                                                                                       hsa:7184    Proteins processing                                                  Cytosol
  T6          gi\|223170     Fibrinogen gamma                                                                                           58      K.EGFGHLSPTGTTEFWLGNEK.I K.MLEEIMKYEASILTHDSSIR.Y K.AIQLTYNPDESSKPNMIDAATLK.S                                                                                                                         hsa:2266    Blood coagulation                                                    Secreted
  T9          gi\|5729877    Heat Shock cognate 71-kDa protein isoform 1                                                                41      K.DAGTIAGLNVLR.I(U)                                                                                                                                                                                   hsa:3312    Stress response, transcription regulation                            Cytosol, nucleus, cell surface
  T11         gi\|2982019    Chain B, Fab Fragment of engineered Human Monoclonal Antibody A5b7                                         47      K.GPSVFPLAPCSR.S/ R.STSESTAALGCLVK.D/ E.VQLLESGGGLVQPGGSLR.L                                                                                                                                          Unknown     Cell defense                                                         Secreted
  T11;12      gi\|178375     Aldehyde dehydrogenase                                                                                     44      K.LPEWAADEPVEK.T/ R.SLEEAIQFINQR.E                                                                                                                                                                    hsa:218     Glycolysis, metabolism of amino acids and xenobiotics                Cytosol
  T13         gi\|4503571    Alpha-enolase isoform 1                                                                                            R.GNPTVEVDLFTSK.G/ R.YISPDQLADLYK.S/ K.WIGMDVAASEFFR.S + Oxidation (M) / K.VNQIGSVTESLQACK.L / K.YNQLLRIEEELGSK.A/                                                                                    hsa:2023    Glicolysis; gliconeogenese                                           Cytosol
                                                                                                                                        90      K.LAMQEFMILPVGAANFR.E + 2 Oxidation (M) /R.EIFDSRGNPTVEVDLFTSK.G/ K.DATNVGDEGGFAPNILENKEGLELLK.T                                                                                                                                                                                       
  T13         gi\|1710248    Protein disulfide isomerase-related protein 5                                                              55      R.TGEAIVDAALSALR.Q/ K.LAAVDATVNQVLASR.Y                                                                                                                                                               hsa:10130   Proteins processing                                                  Endoplasmatic reticulum
  T13         gi\|31170      Chain A, Crystal Structure Of Human Beta Enolase Enob                                                      44      K.VNQIGSVTESIQACK.L                                                                                                                                                                                   hsa:2027    Glicolysis                                                           Cytosol, fosfopiruvat hydratase complex
  T13         gi\|40068518   6-phosphogluconate dehydrogenase, decarboxylating                                                          42      K.IISYAQGFMLLR.Q + Oxidation (M) / K.GILFVGSGVSGGEEGAR.Y                                                                                                                                              hsa:5226    Pentose pathways                                                     Cytosol
  T14         gi\|4505763    Phosphoglycerate kinase 1                                                                                  39      K.ITLPVDFVTADKFDENAK.T                                                                                                                                                                                hsa:5230    Glicolysis                                                           Cytosol
  T14         gi\|306882     Haptoglobin precursor                                                                                      36      K.VTSIQDWVQK.T/ K.SPVGVQPILNEHTFCAGMSK.Y + Oxidation (M)                                                                                                                                              hsa:3240    Defense                                                              Secreted
  T15         gi\|35222      70-kDa heat shock protein                                                                                  43      R.TTPSYVAFTDTER.L (U)                                                                                                                                                                                 hsa:3312    Regulation of cell cycle; cellular membrane organization             Cytosol; plasma membrane
  T16         gi\|63252913   Macrophage-capping protein                                                                                 44      R.QAALQVAEGFISR.M                                                                                                                                                                                     hsa:822     Actin filament organization                                          Cytosol
  T17         gi\|5174391    Alcohol dehydrogenase \[NADP+\]                                                                            44      K.GLVQALGLSNFNSR.Q/ R.GLEVTAYSPLGSSDR.A                                                                                                                                                               hsa:10327   Glicolysis, glicerolipids metabolism                                 Cytosol
  T17         gi\|31397      Fibronectin precursor                                                                                      40      R.VPGTSTSATLTGLTR.G                                                                                                                                                                                   hsa:2335    Angiogenesis, cell adhesion, platelet activation and degranulation   Secreted, extracellular matrix
  T18         gi\|31645      Glyceraldehyde- 3-phosphate dehydrogenase                                                                  46      R.GALQNIIPASTGAAK.A/ R.VPTANVSVVDLTCR.L/ K.LISWYDNEFGYSNR.V/ K.LTGMAFRVPTANVSVVDLTCR.L + Oxidation (M) / K.IKWGDAGAEYVVESTGVFTTMEK.A + Oxidation (M) / K.VIHDNFGIVEGLMTTVHAITATQK.T + Oxidation (M)   hsa:2597    Glycolysis                                                           Cytosol, plasma membrane
  T19;20      gi\|809185     Chain A, The Effect Of Metal Binding On The Structure Of Annexin V And Implications For Membrane Binding   52      RSEIDLFNIRK/ KGLGTDEESILTLLTSRS/ KWGTDEEKFITIFGTRS/ RGTVTDFPGFDERADAETLRK                                                                                                                             hsa:308     Blood coagulation                                                    Cytosol
  T19         gi\|2906146    Malate dehydrogenase precursor                                                                             46      K.IFGVTTLDIVR.A/ K.VDFPQDQLTALTGR.I                                                                                                                                                                   hsa:4191    Citric acid cycle                                                    Mitochondria
  T19         gi\|4826643    Annexin A3                                                                                                 37      K.MLISILTER.S +Oxidation (M)/ K.GAGTNEDALIEILTTR.T                                                                                                                                                    hsa:306     Defense response                                                     Phagocytic vesicle
  T19         gi\|4929769    Glyoxalase domain-containing protein 4 (CGI-150 protein)                                                   36      K.ILTPLVSLDTPGK.A(U)                                                                                                                                                                                  hsa:51031   Unknown                                                              Mitochondria
  T20         gi\|4502599    Carbonyl reductase \[NADPH\] 1                                                                             46      R.LFSGDVVLTAR.D/ R.VVNVSSIMSVR.A/ R.GQAAVQQLQAEGLSPR.F/ K.VADPTPFHIQAEVTMK.T + Oxidation                                                                                                              hsa:873     Lipid metabolism -arachidonic acid                                   Cytosol
  T23         gi\|9844110    cAMP-specific phosphodiesterase 4D                                                                         42      K.LSPVISPR.N                                                                                                                                                                                          hsa:5144    Smooth muscle contraction; regulation of receptor activity           Cytosol
  T24         gi\|2204207    Glutathione S-transferase                                                                                  75      M.PPYTVVYFPVR.G -.MPPYTVVYFPVR.G + Oxidation (M) M.PPYTVVYFPVRGR.C K.EEVVTVETWQEGSLK.A K.FQDGDLTLYQSNTILR.H K.ALPGQLKPFETLLSQNQGGK.T K.YISLIYTNYEAGKDDYVK.A                                           hsa:2940    Amino acids metabolism                                               Cytosol
  T26         gi\|181250     Cyclophilin                                                                                                20      K.TVDNFVALATGEK.G                                                                                                                                                                                     hsa:5480    Signal transduction                                                  Cytosol

###### Proteins identified in pool of patients with non-tumor tissue (Group 2).

  Gel Slice        NCBI ID         Proteins                                                                                                                                                        Score   Representative Peptides                                                                                                                                                              KEGG       Function                                                   Cell Compartment
  ---------------- --------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------- ------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------- ---------------------------------------------------------- -----------------------------
  C1               gi\|78101267    Chain A, Human Complement Component C3                                                                                                                          57      K.TIYTPGSTVLYR.I R.IPIEDGSGEVVLSR.K R.LVAYYTLIGASGQR.E                                                                                                                               hsa:718    Inflammatory response; innate immunity; lipid metabolism   Secreted
  C2               gi\|28243       Filamin A                                                                                                                                                       49      R.IANLQTDLSDGLR.L R.SAGQGEVLVYVEDPAGHQEEAK.V K.LDVQFSGLTK.G K.SPFSVAVSPSLDLSK.I R.EGPYSISVLYGDEEVPR.S R.FGGEHVPNSPFQVTALAGDQPSVQPPLR.S                                               hsa:2316   Actin coupler                                              Cytosol
  C3               gi\|2104553     Myosin heavy chain (MHY11)(5′partial)                                                                                                                           59      K.HAQAVEELTEQLEQFKR.A R.ALEEALEAKEELER.T K.IAQLEEQVEQEAREK.Q                                                                                                                         hsa:4629   Vascular muscle contraction; cell communication            Extracellular matrix
  C7               gi\|34228       Prelamin-A/C isoform 1 precursor; lamin A protein; progerin                                                                                                     56      R.VAVEEVDEEGKFVR.L                                                                                                                                                                   hsa:4000   Intermediate filament                                      Nucleus
  C7               gi\|386758      GRP78 (Glucose-regulated protein 78) precursor                                                                                                                  45      R.ITPSYVAFTPEGER.L R.IINEPTAAAIAYGLDKR.E                                                                                                                                             hsa:3309   Anti-apoptosis                                             Endoplasmic reticulum
  C7               gi\|23200154    Chain A, NMR Structures Of The C-Terminal Globular Domain Of Human Lamin AC                                                                                     43      R.VAVEEVDEEGKFVR.L                                                                                                                                                                   hsa:4000   Structural molecule activity                               Nucleus
  C8               gi\|762885      Plakoglobin                                                                                                                                                     72      K.SAIVHLINYQDDAELATR.A R.ALMGSPQLVAAVVR.T Oxidation (M) R.LVQNCLWTLR.N R.NEGTATYAAAVLFR.I                                                                                            hsa:3728   Cell adhesion, cell migration                              Cytosol; plasmatic membrane
  C8               gi\|642534      Lumican                                                                                                                                                         42      K.SLEYLDLSFNQIAR.L                                                                                                                                                                   hsa:4060   Collagen fibrils organization                              Extracellular matrix
  C8               gi\|110590597   Chain A, Apo-Human Serum Transferrin (Non-Glycosylated)                                                                                                         36      K.FYLGYEYVTAIR.N                                                                                                                                                                     hsa:7018   Mineral absorption                                         Secreted
  C10              gi\|35505       Pyruvate kinase                                                                                                                                                 39      R.TATESFASDPILYRPVAVALDTKGPEIR.T R.EAEAAIYHLQLFEELRR.L                                                                                                                               hsa:5315   Glycolysis                                                 Cytosol; plasmatic membrane
  C11;13; 15; 16   gi\|3411130     Mutant Desmin                                                                                                                                                   48      R.FLEQQNAALAAEVNR.L                                                                                                                                                                  hsa:1674   Cytoskeleton structural protein activity                   Intermediate filament C
  C13              gi\|340219      Vimentin                                                                                                                                                        60      K.ILLAELEQLK.G K.ILLAELEQLKGQGK.S K.LQEEMLQREEAENTLQSFR.Q Oxidation (M) R.KVESLQEEIAFLK.K R.QVQSLTCEVDALKGTNESLER.Q R.EYQDLLNVK.M K.MALDIEIATYR.K Oxidation (M) R.ISLPLPNFSSLNLR.E   hsa:7431   Apoptosis; cell mobility                                   Cytosol
  C13              gi\|704416      Elongation factor Tu                                                                                                                                            45      K.LLDAVDTYIPVPAR.D                                                                                                                                                                   hsa:7284   Oxidative phosphorylation                                  Mitochondria
  C15              gi\|34234       Laminin-binding protein                                                                                                                                         75      R.AIVAIENPADVSVISSR.N R.FTPGTFTNQIQAAFREPR.L                                                                                                                                         hsa:3921   Ribosome                                                   Cytosol
  C16              gi\|47519616    Tropomyosin beta chain isoform 2                                                                                                                                73      R.IQLVEEELDR.A R.IQLVEEELDRAQER.L R.LATALQKLEEAEK.A                                                                                                                                  hsa:7169   Muscle contraction                                         Cytosol
  C17              gi\|31645       Glyceraldehyde-3-phosphate dehydrogenase                                                                                                                        72      K.VIHDNFGIVEGLMTTVHAITATQK.T Oxidation (M) R.DGRGALQNIIPASTGAAK.A R.GALQNIIPASTGAAK.A R.VPTANVSVVDLTCR.L K.LISWYDNEFGYSNR.V                                                          hsa:2597   Glycolysis                                                 Cytosol; plasmatic membrane
  C19              gi\|4505773     Prohibitin                                                                                                                                                      91      R.IFTSIGEDYDER.V R.FDAGELITQR.E                                                                                                                                                      hsa:5245   DNA synthesis                                              Mitochondrial membrane
  C19              gi\|66473265    Beta globin chain                                                                                                                                               50      K.VNVDEVGGEALGR.L R.LLVVYPWTKR.F                                                                                                                                                     hsa:5245   Oxygen transport                                           Hemoglobin
  C21              gi\|494066      Chain A, Three- Dimensional Structure Of Class Pi Glutathione S-Transferase From Human Placenta In Complex With S-Hexylglutathione At2.8 Angstroms Resolution   36      .PPYTVVYFPVRGR.C K.FQDGDLTLYQSNTILR.H                                                                                                                                                hsa:2940   Amino acids metabolism                                     Cytosol

DISCUSSION
==========

A large number of proteins were identified in both Groups 1 and 2. Some of these proteins found in Group 1 are also directly involved in the development of other types of cancers and therefore, suitable for analysis.

The major stress-inducible heat shock protein, Hsp70, that is a chaperone protein abundantly and preferentially expressed in tumors, was detected in Group 1. Owing to the ability of Hsp70 to protect cells from a wide range of apoptotic and necrotic stimuli, it has been assumed that Hsp70 may confer survival advantage to tumor cell lines. Nylandsted et al. ([@B16]) demonstrated that the depletion of Hsp70 by an adenovirus expressing antisense Hsp70 resulted in a massive cell death of tumorigenic cell lines of breast, colon, prostate, and liver. The authors advocate that Hsp70 is a prerequisite for the survival of human cancer cells. Similarly, Aghdassi et al. ([@B17]) demonstrated that the depletion of Hsp70 by short interfering RNA treatment induced apoptosis in pancreatic adenocarcinoma.

Plectin is a cytolinker protein of the plakin family. Plakins connect intermediate filaments to desmosomes and hemidesmosomes, stabilize cells mechanically, regulate cytoskeleton dynamics, and serve as a scaffolding platform for signaling molecules. Niwa et al. ([@B18]) reported that Plectin misexpression leads to displacement of the centrosome, therefore contributing to genomic instability and cancer development. Nevertheless, plectin is not expressed by most normal tissues, with the exception of the skin and genitourinary tract. Interestingly, we have detected plectin solely in Group 1. Complement plays a central part of the innate immune system, providing a highly effective means for destruction of invading microorganisms: clearance of immune complexes; and elimination of dead, apoptotic, and tumor cells. During the evolution of a cancer cell, neo-antigens are produced. These elements distinguish cancer cells from their normal counterparts and may well be recognized by the immune system, eliminating many or most tumors ([@B19], [@B20]). Although most in vivo observations support that many cancers activate the autologous complement system, it is also well-known that the efficiency of complement-mediated tumor cytotoxicity is hampered by various protective mechanisms ([@B21]). In this work, human complement C3 was detected only in Group 2. A possible explanation for these findings lies on the theory that patients with malignancies have a poorer immune response. Our result corroborates the study of Ornellas et al. ([@B22]), in which the authors have demonstrated that human complement fragments C3 and C4A/B were downregulated in plasma of patients with SCCP. In the present series, all patients from Group 1 were HPV positive and this could explain the absence of complement C3 because viral proteins counteract the immune response ([@B23]).

Enolase is a key glycolytic enzyme that has been used as a diagnostic marker to identify human lung cancers ([@B24]). Higher α-enolase plasma levels were also identified in patients with renal cell carcinoma ([@B25]). In cancer cells, enolase is overexpressed and localizes on their surface, where it acts as a key protein in tumor metastasis, promoting cellular metabolism in anaerobic conditions and driving tumor invasion through plasminogen activation and extracellular matrix degradation. It also displays a characteristic pattern of acetylation, methylation, and phosphorylation that regulates protein functions and immunogenicity. In the present study, alfa and beta enolase isoforms were identified exclusively in Group 1. This finding may suggest that in the future, enolase can be used as a possible clinical biomarker. Nevertheless, further studies are needed to corroborate these findings and to determine the usefulness of this protein in clinical scope.

Prohibitin is a potential tumor suppressor, which was originally identified because of its anti-proliferative activities. The human prohibitin gene was identified and cloned in 1991, as a result of a search for potential tumor suppressors, on the basis of its anti-proliferative activities ([@B26]). Furthermore, prohibitin is capable of inhibiting cell proliferation by repressing the transcriptional activity mediated by E2F which regulates many genes involved in the transition G1/S and DNA synthesis ([@B27]). In addition to transcriptional repression, prohibitin can induce p53-mediated transcription, indicating that prohibitin may have dual functions in modulating transcription ([@B28]).

In a study conducted by Joshi et al. ([@B29]), the authors supported this theory by demonstrating that prohibitin can differentially regulate the Yin-Yang 1 and caspase 7 gene promoter activities. Additional functions related to prohibitin were linked to cell apoptosis ([@B30]). In this series, prohibitin was exclusively presented in Group 2, supporting its potential tumor suppressor activity. The critical functions of prohibitin in growth control and transcriptional regulation clearly indicate the need for further investigations to elucidate its importance in SCCP development.

To our knowledge this is the first study that analyzed penile tumors through proteomics technologies. Unfortunately, as all samples in our analysis were typed as HPV +, it was not possible to perform a comparison concerning HPV status in the group with tumor. As the selected patients were positive for HPV DNA, this fact can cause false negative for complement proteins. The variability could have been better analyzed if there were compared to patients with cancer of the penis, whose tests did not reveal the presence of HPV. The proteomic consequences of HPV infection in penile carcinoma are not known. Analysis of differentially expressed proteins by HPV status revealed enrichment of proteins involved in epithelial cell development, keratinization and extracellular matrix organization in HPV- oropharyngeal carcinoma (OPC), whereas enrichment of proteins in DNA initiation and replication and cell cycle control was found for HPV+ (OPC) ([@B31]). Due to the rarity of penile tumors and the high percentage of HPV positive in our samples ([@B8], [@B13]) it is difficult to compare the tumors according to HPV status. However, a second study is underway to compare our results and identify the presence or absence of complement in tissue of SCCP patients negative for HPV.

CONCLUSIONS
===========

We identified a large number of proteins in patients with penile cancer and in the control group. Some of these proteins, found in the first group, are also directly involved in the development of other types of cancers and therefore, suitable for analysis. Further studies are needed to corroborate these findings and to determine the usefulness of each discussed protein in the clinical scope of SCCP patients. Remarkably, this work reinforces that the C3 complement protein is a strong biomarker candidate for evaluating SCCP patients. Further studies should be conducted comparing samples positive for HPV with other HPV negative.
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